瑞格列奈联合阿卡波糖治疗2型糖尿病的临床效果及HbA1c、FPG、2 hPG水平影响评价

目的分析瑞格列奈联合阿卡波糖治疗2型糖尿病的临床效果及对HbA1c、FPG、2 hPG水平的影响。方法该次研究中的88例观察对象均抽选于2019年4月—2020年4月在该院接受治疗的2型糖尿病患者当中。应用数字随机分组的方式将患者分为两组,对照组患者接受瑞格列奈联合盐酸二甲双胍治疗,观察组患者给予瑞格列奈联合阿卡波糖,两组患者均接受为期3个月的用药治疗,比较其血糖水平改善情况、临床疗效以及不良反应发生情况。结果治疗前,观察组和对照组患者的空腹血糖(FPG)、餐后2 h血糖(2 hPG)以及糖化血红蛋白(HbA1c)水平相比,差异无统计学意义(P>0.05),治疗后观察组患者的空腹血糖、餐后2 h血糖和糖化血红蛋白均明显低于治疗前和对照组,差异有统计学意义(P<0.05);观察组患者的临床总好转率相比较于对照组,明显更高,差异有统计学意义(P<0.05);观察组患者的不良反应发生率与对照组相比较,差异无统计学意义(P>0.05)。结论瑞格列奈联合阿卡波糖治疗2型糖尿病的临床疗效显著,可有效控制患者的血糖水平,且安全性较高。

The Clinical Effect of Repaglinide Combined with Acarbose in the Treatment of Type 2 Diabetes and the Impact Evaluation of HbAlc,FPG and 2 hPG Levels

Objective To analyze the clinical effect of repaglinide combined with acarbose in the treatment of type 2 diabetes and its influence on the levels of HbA1c,FPG and 2 hPG.Methods The observation subjects in this study were selected from patients with type 2 diabetes who were treated in the hospital,from April 2019 to April 2020.The patients were divided into two groups by numerical randomization.The control group received repaglinide combined with metformin hydrochloride treatment,and the observation group received repaglinide combined with acarbose.Both groups received three months of treatment for medication,compared the improvement of blood glucose level,clinical efficacy and occurrence of adverse reactions.Results Before treatment,compared with the fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG)and glycosylated hemoglobin(HbA1c)levels of the observation group and the control group,and the difference was not statistically significant(P>0.05).After treatment,the fasting blood glucose and postprandial blood glucose,2 h blood glucose and glycosylated hemoglobin of the observation group were significantly lower than before treatment and the control group,and the difference was statistically significant(P<0.05);the total clinical improvement rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05);the incidence of adverse reactions in the observation group was similar to that of the control group,and the difference was not statistically significant(P>0.05).Conclusion Repaglinide combined with acarbose has a significant clinical effect in the treatment of type 2 diabetes.It can effectively control the blood glucose level of patients with high safety.